Future directions in soft tissue sarcoma treatment

Francis Hall, Victor Villalobos, Breelyn Wilky

Research output: Contribution to journalReview article

5 Scopus citations

Abstract

Sarcoma is a broad term for mesenchymal malignancies that arise from soft tissue or bone. Despite classification by histologic subtype, clinical behavior and response to therapy have great variability. Modern genetic sequencing techniques have been able to identify additional genetic variability and subsequently new targeted therapies. In this review, we discuss the current state of STS diagnostics and treatment and explore some of the more promising areas in which progress is being made. We discuss therapies targeting PDGFRα/KIT, β-Catenin/APC/NOTCH, IDH-1/2 mutations, MDM2 amplifications, EZH2/INI1 expression loss, ALK fusion, and ASPSCR1-TFE3 fusion. We also discuss the progress that has been made within immunotherapies. While soft tissue sarcomas still portend a poor prognosis, these targeted therapies and immunotherapies provide treatment with less toxic side effects.

Original languageEnglish (US)
JournalCurrent Problems in Cancer
DOIs
StatePublished - Jan 1 2019
Externally publishedYes

Keywords

  • ALK fusion
  • ASPSCR1-TFE3 fusion
  • EZH2/INI1
  • IDH mutation
  • Immunotherapy
  • KIT
  • MDM2
  • PDGFRα
  • Sarcoma
  • Soft tissue sarcoma
  • Targeted therapy
  • β-catenin/APC/NOTCH

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Future directions in soft tissue sarcoma treatment'. Together they form a unique fingerprint.

  • Cite this